{"id":"voglibose","rwe":[{"pmid":"41849948","year":"2026","title":"Design, synthesis of novel methyl-glycosyl furanose based sulfonium type α-glucosidase inhibitors with potent antihyperglycemic activity.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41845153","year":"2026","title":"Evaluation of novel topiramate-phenolic acid conjugates as potent pancreatic α-amylase inhibitors: in vitro and in silico insights.","finding":"","journal":"Journal of computer-aided molecular design","studyType":"Clinical Study"},{"pmid":"41800662","year":"2026","title":"Discovery of Novel C-glycosyl Pyranose-Based Sulfonium and Selenonium Salts Targeting α-Glucosidase with Potent Antihyperglycemic Activity.","finding":"","journal":"Journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41730617","year":"2026","title":"Glucocorticoid Therapy and Miglitol Ameliorate Reactive Hypoglycemia Secondary to Late Dumping Syndrome: A Case Report.","finding":"","journal":"Internal medicine (Tokyo, Japan)","studyType":"Clinical Study"},{"pmid":"41543257","year":"2026","title":"Construction of Versatile Cascade Detection Platforms for Biomolecules Based on a Fluorescent Yttrium Metal-Organic Framework.","finding":"","journal":"ACS applied materials & interfaces","studyType":"Clinical Study"}],"tags":[{"label":"voglibose","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Lysosomal alpha-glucosidase","category":"target"},{"label":"GAA","category":"gene"},{"label":"MGAM","category":"gene"},{"label":"A10BF03","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"},{"label":"Glucosylceramide beta-glucosidase deficiency","category":"indication"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Glycoside Hydrolase Inhibitors","category":"pharmacology"},{"label":"Hypoglycemic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":190.744,"date":"","count":91,"signal":"Hypoglycaemia","source":"DrugCentral FAERS","actionTaken":"Reported 91 times (LLR=191)"},{"llr":150.4,"date":"","count":61,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=150)"},{"llr":124.249,"date":"","count":33,"signal":"Pneumatosis intestinalis","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=124)"},{"llr":92.722,"date":"","count":68,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 68 times (LLR=93)"},{"llr":92.29,"date":"","count":59,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=92)"},{"llr":60.16,"date":"","count":38,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=60)"},{"llr":53.508,"date":"","count":21,"signal":"Pemphigoid","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=54)"},{"llr":50.935,"date":"","count":33,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=51)"},{"llr":45.083,"date":"","count":22,"signal":"Diabetes mellitus inadequate control","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=45)"},{"llr":41.595,"date":"","count":48,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 48 times (LLR=42)"},{"llr":38.887,"date":"","count":41,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=39)"},{"llr":38.415,"date":"","count":8,"signal":"Thrombotic cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=38)"},{"llr":37.381,"date":"","count":12,"signal":"Hypoglycaemic coma","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=37)"},{"llr":35.116,"date":"","count":23,"signal":"Altered state of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=35)"},{"llr":34.725,"date":"","count":13,"signal":"Ketoacidosis","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=35)"}],"commonSideEffects":[],"contraindications":["Breastfeeding (mother)","Impaired renal function disorder","Peripheral nerve disease","Pregnancy, function"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VOGLIBOSE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:05:14.837169+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:05:36.476712+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:05:22.385006+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VOGLIBOSE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:05:23.142416+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Alpha glucosidase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:05:23.721556+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL476960/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:05:23.620591+00:00"}},"allNames":"glustat","offLabel":[],"synonyms":["voglibose","glustat","voglistat","AO-128"],"timeline":[{"date":"1994-08-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"aiSummary":"Voglibose, marketed as Glustat, is an enzyme inhibitor used primarily for treating Type 2 Diabetes Mellitus, currently positioned in a competitive market with off-patent alternatives like acarbose and miglitol. Its key strength lies in its mechanism of action, specifically inhibiting Lysosomal alpha-glucosidase, which differentiates it from other alpha-glucosidase inhibitors. The primary risk to Glustat is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.","approvals":[{"date":"1994-08-20","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Glustat","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000},{"indication":"Glucosylceramide beta-glucosidase deficiency","otherDrugs":[{"name":"eliglustat","slug":"eliglustat","company":"Genzyme Corp"},{"name":"imiglucerase","slug":"imiglucerase","company":"Genzyme"},{"name":"miglustat","slug":"miglustat","company":"Actelion Pharms Ltd"}],"globalPrevalence":null}],"mechanism":{"target":"Lysosomal alpha-glucosidase","targets":[{"gene":"GAA","source":"DrugCentral","target":"Lysosomal alpha-glucosidase","protein":"Lysosomal alpha-glucosidase"},{"gene":"MGAM","source":"DrugCentral","target":"Maltase-glucoamylase, intestinal","protein":"Maltase-glucoamylase, intestinal"}],"modality":"Small Molecule","drugClass":"voglibose","explanation":"","oneSentence":"","technicalDetail":"Glustat (voglibose) is a competitive inhibitor of Lysosomal alpha-glucosidase, a key enzyme involved in the breakdown of carbohydrates in the lysosomes of cells. By inhibiting this enzyme, Glustat reduces the activity of Lysosomal alpha-glucosidase, leading to decreased glucose release into the bloodstream."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2845","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VOGLIBOSE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VOGLIBOSE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:14:35.219478","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:05:36.477186+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"acarbose","drugSlug":"acarbose","fdaApproval":"1995-09-06","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"miglitol","drugSlug":"miglitol","fdaApproval":"1996-12-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"voglibose","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"},{"name":"Glucosylceramide beta-glucosidase deficiency","source":"DrugCentral","snomedId":190794006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acarbose","brandName":"acarbose","genericName":"acarbose","approvalYear":"1995","relationship":"same-class"},{"drugId":"miglitol","brandName":"miglitol","genericName":"miglitol","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01242202","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":["Type 2 Diabetes Mellitus"],"enrollment":113,"completionDate":"2012-05-25"},{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":["Diabetes Mellitus Type 2 Without Complication"],"enrollment":118,"completionDate":"2024-01"},{"nctId":"NCT01309698","phase":"PHASE4","title":"Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":["Type 2 Diabetes"],"enrollment":24,"completionDate":""},{"nctId":"NCT02049814","phase":"PHASE4","title":"Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05-09","conditions":["Type 2 Diabetes Mellitus"],"enrollment":494,"completionDate":"2016-06-28"},{"nctId":"NCT01993927","phase":"","title":"Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance \"Long-term Use in Patients With Impaired Glucose Tolerance\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11-18","conditions":["Impaired Glucose Tolerance"],"enrollment":742,"completionDate":"2013-08-31"},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":["Type 2 Diabetes Mellitus"],"enrollment":585,"completionDate":"2014-05-08"},{"nctId":"NCT00212017","phase":"NA","title":"Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT","status":"TERMINATED","sponsor":"National Cerebral and Cardiovascular Center, Japan","startDate":"2005-04","conditions":["Impaired Glucose Tolerance","Myocardial Infarction"],"enrollment":3000,"completionDate":"2017-08"},{"nctId":"NCT00837577","phase":"PHASE3","title":"MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":["Diabetes Mellitus, Non-Insulin-Dependent"],"enrollment":133,"completionDate":"2010-08-11"},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1417914,"completionDate":"2015-04"},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1499650,"completionDate":"2015-05"},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":886172,"completionDate":"2015-04"},{"nctId":"NCT00411554","phase":"PHASE3","title":"A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":["Diabetes Mellitus, Non-Insulin-Dependent"],"enrollment":319,"completionDate":"2007-08"},{"nctId":"NCT02287402","phase":"PHASE4","title":"Postmarketing Clinical Study on AO-128","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-03","conditions":["Impaired Glucose Tolerance (IGT)"],"enrollment":197,"completionDate":"2012-11"},{"nctId":"NCT02097342","phase":"PHASE4","title":"Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-12","conditions":["Type 2 Diabetes Mellitus","Insulin Sensitivity/Resistance"],"enrollment":30,"completionDate":"2015-01"},{"nctId":"NCT00970528","phase":"PHASE4","title":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-11","conditions":["Diabetes Mellitus, Type 2"],"enrollment":124,"completionDate":"2012-03"},{"nctId":"NCT00654381","phase":"PHASE3","title":"Japanese P III vs Voglibose and Placebo","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":["Diabetes Mellitus, Type 2"],"enrollment":561,"completionDate":""},{"nctId":"NCT00663884","phase":"PHASE4","title":"Glufast On Insulin Glargine Trial in Type 2 DM","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2008-02","conditions":["Diabetes Mellitus, Type 2"],"enrollment":167,"completionDate":"2009-09"},{"nctId":"NCT01263483","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":230,"completionDate":"2008-04"},{"nctId":"NCT01263470","phase":"PHASE2","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":480,"completionDate":"2007-12"},{"nctId":"NCT01263496","phase":"PHASE2","title":"Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-05","conditions":["Type 2 Diabetes Mellitus"],"enrollment":438,"completionDate":"2008-09"},{"nctId":"NCT01263509","phase":"PHASE2,PHASE3","title":"Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":["Type 2 Diabetes Mellitus"],"enrollment":179,"completionDate":"2008-10"},{"nctId":"NCT01055652","phase":"PHASE1","title":"Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":28,"completionDate":"2010-04"},{"nctId":"NCT00724542","phase":"NA","title":"Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.","status":"UNKNOWN","sponsor":"Ministry of Science and Technology of the People´s Republic of China","startDate":"2008-07","conditions":["Coronary Heart Disease","Impaired Glucose Tolerance"],"enrollment":1600,"completionDate":"2010-12"},{"nctId":"NCT00368134","phase":"PHASE3","title":"To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":["Diabetes Mellitus, Type 2"],"enrollment":370,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010940","UNII":"S77P977AG8","CHEBI":"CHEBI:32300","INN_ID":"6797","UMLSCUI":"C0532578","chemblId":"CHEMBL476960","ChEMBL_ID":"CHEMBL476960","KEGG_DRUG":"D01665","DRUGBANK_ID":"DB04878","PDB_CHEM_ID":" VOG","PUBCHEM_CID":"444020","SNOMEDCT_US":"1163442006","MESH_SUPPLEMENTAL_RECORD_UI":"C102817"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"6%"},"publicationCount":393,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BF03","allCodes":["A10BF03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 10","pmid":"41849948","title":"Design, synthesis of novel methyl-glycosyl furanose based sulfonium type α-glucosidase inhibitors with potent antihyperglycemic activity.","journal":"European journal of medicinal chemistry"},{"date":"2026 Mar 18","pmid":"41845153","title":"Evaluation of novel topiramate-phenolic acid conjugates as potent pancreatic α-amylase inhibitors: in vitro and in silico insights.","journal":"Journal of computer-aided molecular design"},{"date":"2026 Mar 26","pmid":"41800662","title":"Discovery of Novel C-glycosyl Pyranose-Based Sulfonium and Selenonium Salts Targeting α-Glucosidase with Potent Antihyperglycemic Activity.","journal":"Journal of medicinal chemistry"},{"date":"2026 Feb 24","pmid":"41730617","title":"Glucocorticoid Therapy and Miglitol Ameliorate Reactive Hypoglycemia Secondary to Late Dumping Syndrome: A Case Report.","journal":"Internal medicine (Tokyo, Japan)"},{"date":"2026 Jan 28","pmid":"41543257","title":"Construction of Versatile Cascade Detection Platforms for Biomolecules Based on a Fluorescent Yttrium Metal-Organic Framework.","journal":"ACS applied materials & interfaces"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1994","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"1994-08-20T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:05:36.477186+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}